Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT05884723 Sponsor: Anton Skaro Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT05884723
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who are scheduled to have part of their liver removed (either through open surgery or keyhole surgery) because cancer has spread to the liver from the bowel or rectum
  • People who have signs of fatty liver disease, shown on a scan (CT or MRI) or a tissue sample taken before surgery
  • People who are able to use a smartphone app to record and track what they eat during the diet part of the study

Who may not be able to join:

  • People who are having liver surgery for any reason other than bowel or rectal cancer that has spread to the liver
  • People who are currently taking a type of diabetes medication called SGLT-2 inhibitors (examples include medications such as dapagliflozin or empagliflozin) (confirm with trial site)
  • People who do not have signs of fatty liver disease
  • People who have signs of liver scarring (fibrosis) or severe liver damage (cirrhosis), detected through blood tests or scans done before surgery
  • People whose fatty liver disease is caused by alcohol use
  • People who have a known condition that affects blood clotting

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Anton Skaro, MD PhD, London Health Sciences Centre/Lawson Health Research Institute

Phone: 519-685-8500

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Anton Skaro
Registry
ClinicalTrials.gov
Start date
1 May 2024
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Perioperative blood transfusion

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov